mexidol-package-2
mexidol-instruction
mexidol-package-2
mexidol-instruction

MEXIDOL ®

Clear
Bulk deal
Quantity Discount Discounted price
2 5% -
3 8% -
4 10% -
5 12% -
6 14% -
7 16% -
8 + 18% -
Bulk pricing will be applied to package:

Buy Mexidol with 3-7 day fast domestic delivery within the US ($5) – just choose “ships from US (+15%) 

We have the best refund policy and delivery terms among other vendors!

Mexidol® is a unique development of the Russian pharmaceutical industry. Due to the universal mechanism of action and a wide range of pharmacological effects, Mexidol® is effective in the treatment of acute and chronic diseases caused by ischemia and hypoxia of various origins. Nowadays the drug is widely used in neurology, therapy, cardiology, psychiatry, and narcology. Mexidol® is produced at leading pharmaceutical manufacturing sites in the Russian Federation, which operate in accordance with GMP (Good Manufacturing Practice) production and quality control standards.

The development of Mexidol® is closely associated with the name of the Soviet chemist N.N. Semenov, who was awarded the Nobel Prize in Chemistry for his piece of research on free radicals in 1956. Understanding the mechanisms of the free radical formation became the basis for creating the concept of combating tissue ischemia and for developing drugs with antioxidant and antihypoxic activity. The work on Mexidol® was continued by the students of N.N. Semenov in the 1980s. The drug has been in clinical practice since the middle 1990s.

We also sell a close analogue of Mexidol – Ethoxidol. Be sure to check it out, as it is more effective than Mexidol in some cases! 

The presence of succinate in the structure of Mexidol® is of fundamental importance for the manifestation of its pharmacological effects since succinate is functionally significant for many processes in the body. In particular, it is a substrate for increasing the energy metabolism in the cell. Due to its properties, free radicals, which have a damaging effect on the cellular structures, are deactivated.

Mexidol® is known to treat the followings diseases:

  • Neurological problems: vegetovascular dystonia, acute cerebral circulation disorders, cognitive problems associated with cerebral arteriosclerosis (impaired memory, speech, loss of basic skills, etc.);
  • In psychiatry: withdrawal syndrome (alcohol or drug withdrawal), anxiety, neurosis, intoxication with drugs from the group of antipsychotics;
  • In surgery: for the complex treatment of acute purulent-inflammatory processes in the peritoneum.

Country of Manufacture: Russia. Produced by Pharmasoft.

Take your chance to buy Mexidol at the best price!


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Dosage and Administration 

The drug is taken orally, 1-2 pills 3 times a day, maximum daily dose is 6 pills. The general period of therapy is 2-6 weeks. The duration of the therapy for the alcohol abstinence treatment is 5-7 days. The duration of treatment in case of ischemic heart disease is 1.5 – 2 months or more.

Contraindications

Hypersensitivity, acute kidney and liver diseases. Pregnancy and lactation.

Side Effects & Overdose

Allergic reactions are possible. The patient may feel drowsiness in case of an overdose. Hence special caution must be taken when driving vehicles and engaging in other potentially dangerous activities.

Awards:

  • 2003 – award of the Government of the Russian Federation for the development and implementation of Mexidol® in clinical practice;
  • 2014 – Russian Pharma Awards in the nomination “The Drug of Choice in the Treatment of Ischemic Disorders Caused by Cerebral Spasm”;
  • 2016 – “Molecule of Life” award of the Russian Scientific Medical Community of Therapists.
  1. Ivanov et al (2002) Effectiveness of mexidol in acute pancreatitis https://www.ncbi.nlm.nih.gov/pubmed/12416225
  2. Garazha et al (2006) Efficacy of the use of antioxidant preparation mexidol in comprehensive treatment of inflammatory diseases of parodontium https://www.ncbi.nlm.nih.gov/pubmed/17310943
  3. Voronina et al (2007) Mexidol effects in extreme conditions (experiments with animals) https://www.ncbi.nlm.nih.gov/pubmed/18672520
  4. Volchegorskii et al (2008) Effect of alpha-lipoic acid and mexidol on neuro- and the affective status in patients at early stages of diabetic foot syndrome https://www.ncbi.nlm.nih.gov/pubmed/19069461
  5. L Abramenko et al (2011) The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy https://www.ncbi.nlm.nih.gov/pubmed/22611676
  6. Volchegorkii et al (2011) Comparative study of alpha-lipoic acid and mexidol effects on affective status, cognitive functions and quality of life in diabetes mellitus patients https://www.ncbi.nlm.nih.gov/pubmed/22288155
  7. Tsublova et al (2012) Studies on actoprotective and antihypoxic properties of new succinate-containing benzothiazole derivatives https://www.ncbi.nlm.nih.gov/pubmed/23074949
  8. Motin et al (2012) Electrophysiological study of the mechanism of mexidol action https://www.ncbi.nlm.nih.gov/pubmed/22442954
  9. Shchul’kin et al (2014) A comparative study of mexidol and mexiprim pharmacokinetic parameters https://www.ncbi.nlm.nih.gov/pubmed/25591654
  10. Androfagina et al (2015) Mexidol in the rehabilitation of patients in the acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/26978645
  11. V Sergin, T Dronova (2015) The use of mexidol in the intensive treatment of acute severe ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/26121002
  12. Chukanova et al (2015) The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/26081329
  13. Berezhnaya et al (2016) The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia https://www.ncbi.nlm.nih.gov/pubmed/27240176
  14. Povarnina et al (2017) Comparison of the Pharmacological Effects of Dimeric Dipeptide Nerve Growth Factor Mimetic GK-2 and Mexidol on the Model of Ischemic Stroke in Rats https://www.ncbi.nlm.nih.gov/pubmed/29181667
  15. Stakhovskaya et al (2017) Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA) https://www.ncbi.nlm.nih.gov/pubmed/28665371
  16. Volchegorskii et al (2017) Anxiolytic and antidepressant effects of emoxipine, reamberin and mexidol in experimental diabetes mellitus https://www.ncbi.nlm.nih.gov/pubmed/28638031
  17. Gromova et al (2017) A study of the neuroprotective effect of mexidol on the cell model of glutamate stress https://www.ncbi.nlm.nih.gov/pubmed/29376987
  18. N Kulai, E Kovalchuk (2018) Assessment of the efficacy of mexidol in the combination with hyperbaric oxygen in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/29798984
  19. Zamoshchina et al (2018) Effect of mexidol on physical working capacity and level of lactate in the blood of rats in conditions of light deprivation https://www.ncbi.nlm.nih.gov/pubmed/30585610
  20. Gromova et al (2018) Experience with mexidol in neurological practice https://www.ncbi.nlm.nih.gov/pubmed/30499505
  21. Yakusheva et al (2018) An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia https://www.ncbi.nlm.nih.gov/pubmed/29927406
  22. Godunova et al (2018) An influence of submaximal (submineximal) doses of mexidol on oxidant stress and inflammation in the acute period of ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/29560937
  23. E Dyakonova, V Makerova (2018) Mono- and combination therapy with the mexidol in young patients with cerebral angiodystonia https://www.ncbi.nlm.nih.gov/pubmed/30251978
  24. E Polozova (2018) Preventive therapy with mexidol in toxic damage to the heart https://www.ncbi.nlm.nih.gov/pubmed/29697688

Related products

Picamilon® is based on a synthetic combination of GABA and niacin, with the former being responsible for reducing neuronal excitability and the latter acting as a strong vasodilator. Its effects are similar to those of Phenibut, as both drugs reduce anxiety and improve mood. However, unlike Phenibut, Picamilon® has a much stronger impact on energy metabolism in the brain because it stimulates consumption of oxygen and glucose by neuronal tissue.

The main substance of Pantogam Active® is a hopantenic acid developed in Japan in 1950. The hopantenic acid combines GABA and vitamin B5 that allows GABA to reach neurons of the central nervous system. GABA is the chief inhibitory neurotransmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability throughout the nervous system. Pantogam Active stabilizes neurotransmitters, i.e. makes them more resistant to temporary or permanent negative effects.

Deltaran® is a powerful neuroprotector that has a powerful antioxidant, stress protective and antidepressant effect. It protects neurons from the destruction by toxic, infectious and other damaging agents, and also prevents the death of nerve cells because of stress. The use of Deltaran® makes it possible to compensate for the deficiency of endogenous neuroprotectors in the body, which ensures unimpaired functioning of the central nervous system in extreme situations.

ADAPTOL ® (Mebicar)

$ 18.00$ 46.00

Mebicar (or tetramethylglycoluril) is an anxiolytic medication that works on the serotonergic system: taken in small doses it increases the effect of tryptophan, which is a precursor to serotonin. Mebicar purportedly has anti-anxiety properties. It is also used to aid smoking cessation and in the treatment of ADHD symptoms. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.